Amgen (AMGN) Assets (2009 - 2026)
Amgen (AMGN) posted quarterly Assets of $92.5 billion for Q1 2026, up 3.51% year-over-year from $89.4 billion in Q1 2025, and up 2.12% on a QoQ basis from $90.6 billion in Q4 2025.
Amgen (AMGN) Assets (2009 - 2026) Analysis & Trends
Amgen (AMGN) has reported Assets for 18 consecutive years, with $92.5 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets rose 3.51% year-over-year to $92.5 billion; the TTM figure through Mar 2026 stood at $92.5 billion (up 3.51% YoY), while the FY2025 annual figure was $90.6 billion, down 1.36% from the prior year.
- Assets came in at $92.5 billion for Q1 2026 at Amgen, up from $90.6 billion in the prior quarter.
- The five-year high for Assets was $97.2 billion in Q4 2023, with the low at $59.2 billion in Q1 2022.
- Average Assets over 5 years is $84.2 billion, with a median of $90.3 billion recorded in 2023.
- Across the five-year window, Assets soared 52.24% in 2023 and slipped 5.47% in 2024, its largest moves.
- Year by year, Assets stood at $65.1 billion in 2022, then surged by 49.19% to $97.2 billion in 2023, then decreased by 5.47% to $91.8 billion in 2024, then slipped by 1.36% to $90.6 billion in 2025, then advanced by 2.12% to $92.5 billion in 2026.
- According to Business Quant data, Assets over the past three periods registered $92.5 billion, $90.6 billion, and $90.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 116.58 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 200.89 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 136.46 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 114.02 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 128.69 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 92.50 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 56.28 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 208.00 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 29.48 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 92.50 Bn |
| Dec 31, 2025 | 90.59 Bn |
| Sep 30, 2025 | 90.14 Bn |
| Jun 30, 2025 | 87.90 Bn |
| Mar 31, 2025 | 89.37 Bn |
| Dec 31, 2024 | 91.84 Bn |
| Sep 30, 2024 | 90.88 Bn |
| Jun 30, 2024 | 90.91 Bn |
| Mar 31, 2024 | 92.98 Bn |
| Dec 31, 2023 | 97.15 Bn |
| Sep 30, 2023 | 90.53 Bn |
| Jun 30, 2023 | 90.27 Bn |
| Mar 31, 2023 | 88.72 Bn |
| Dec 31, 2022 | 65.12 Bn |
| Sep 30, 2022 | 63.70 Bn |
| Jun 30, 2022 | 59.29 Bn |
| Mar 31, 2022 | 59.20 Bn |
| Dec 31, 2021 | 61.17 Bn |
| Sep 30, 2021 | 64.99 Bn |
| Jun 30, 2021 | 59.77 Bn |